Abstract:Abstract Background Currently, few studies focus on the association between gut microbiota and systemic lupus erythematosus (SLE), and much less studies consider the effect of drug usage. Proton pump inhibitors (PPIs) are commonly used to treat drug-related gastrointestinal damage in SLE patients. Therefore, the purpose of this study is to examine the gut microbiota of SLE patients using PPIs. Methods Fecal samples from 20 SLE patients with PPIs (P-SLE), 20 SLE patients without PPIs (NP-SLE) and 17 healthy controls (HCs) were obtained. The structure of the bacterial community in the fecal samples was analyzed by 16S rRNA gene sequencing. Redundancy analysis (RDA) was performed to observe the relationship between clinical variables and microbiome composition in P-SLE and NP-SLE patients. Based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, functional capabilities of microbiota were estimated. Network analysis was performed to analyze the association of metabolic pathway alterations with altered gut microbiota in P-SLE and NP-SLE patients. Results P-SLE patients exhibited increased alpha-diversity and an altered composition of the gut microbiota compared with NP-SLE patients. The alpha-diversity of NP-SLE patients was significantly lower than HCs but also of P-SLE patients, whose alpha-diversity had become similar to HCs. Compared with NP-SLE patients, the relative abundances of Lactobacillus , Roseburia , Oxalobacter , and Desulfovibrio were increased, while those of Veillonella , Escherichia , Morganella , Pseudomonas and Stenotrophomonas were decreased in P-SLE patients. RDA indicated that PPI use was the only significant exploratory variable for the microbiome composition when comparing SLE patients. KEGG analysis showed that 16 metabolic pathways were significantly different between NP-SLE and P-SLE patients. These metabolic pathways were mainly associated with changes in Escherichia , Roseburia , Stenotrophomonas , Morganella and Alipipes as determined by the network analysis. Conclusions PPI use is associated with an improved microbiome composition of SLE patients as it 1) increases alpha-diversity levels back to normal, 2) increases the abundance of various (beneficial) commensals, and 3) decreases the abundance of certain opportunistic pathogenic genera such as Escherichia . Validation studies with higher patient numbers are however recommended to explore these patterns in more detail.

What problem does this paper attempt to address?

This paper primarily explores the impact of proton pump inhibitors (PPIs) on the gut microbiome composition of patients with systemic lupus erythematosus (SLE). ### Research Background and Objectives - **Research Background**: Although previous studies have shown that the gut microbiome of SLE patients has changed, there is limited research on the impact of medication use on these changes. PPIs are commonly used to treat gastrointestinal damage in SLE patients. - **Research Objectives**: The aim is to analyze the gut microbiome structure of SLE patients using PPIs (P-SLE) compared to SLE patients not using PPIs (NP-SLE) and healthy controls (HCs) through 16S rRNA gene sequencing, and to explore the association between PPI use and the gut microbiome composition in SLE patients. ### Main Findings - **Changes in Microbial Diversity**: Compared to NP-SLE patients, the gut microbiome α-diversity of P-SLE patients increased; whereas the α-diversity of NP-SLE patients was significantly lower than that of HCs. - **Changes in Microbial Composition**: - At the genus level, compared to NP-SLE patients, the relative abundance of *Lactobacillus*, *Roseburia*, *Oxalobacter*, and *Desulfovibrio* increased in P-SLE patients; while the relative abundance of *Veillonella*, *Escherichia*, *Morganella*, *Pseudomonas*, and *Stenotrophomonas* decreased. - These changes made the microbial composition of P-SLE patients more similar to that of HCs. - **Changes in Metabolic Pathways**: Through analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, 16 metabolic pathways were found to be significantly different between NP-SLE and P-SLE patients. These pathways were mainly related to changes in *Escherichia*, *Roseburia*, *Stenotrophomonas*, *Morganella*, and *Alipipes*. ### Conclusion - The use of PPIs is associated with an improvement in the gut microbiome composition of SLE patients, specifically manifested as the restoration of α-diversity, an increase in the abundance of beneficial symbiotic bacteria, and a decrease in the abundance of certain opportunistic pathogenic genera such as *Escherichia*. - Further large-sample validation studies are needed to explore these patterns in depth. ### Method Overview - **Study Subjects**: Included 20 SLE patients using PPIs (P-SLE), 20 SLE patients not using PPIs (NP-SLE), and 17 healthy controls (HCs). - **Sample Collection and Processing**: Fecal samples were collected, DNA was extracted, and the gut microbiome structure was analyzed through 16S rRNA gene sequencing. - **Data Analysis**: Bioinformatics tools were used for sequence quality control, OTU clustering, species annotation, and other steps. This paper reveals the impact of PPIs on the gut microbiome of SLE patients through empirical research, providing a new perspective for further understanding the pathogenesis and treatment of SLE.

Proton pump inhibitors induce changes in the gut microbiome composition of systemic lupus erythematosus patients

Disordered intestinal microbes are associated with the activity of Systemic Lupus Erythematosus.

Proton pump inhibitors alter gut microbiota by promoting oral microbiota translocation: a prospective interventional study

Gut Microbiota in Systemic Lupus Erythematosus and Correlation With Diet and Clinical Manifestations

Association between systemic lupus erythematosus and disruption of gut microbiota: a meta-analysis

Salivary microbiota composition before and after use of proton pump inhibitors in patients with laryngopharyngeal reflux: a self-control study

Gut Microbiota in Systemic Lupus Erythematosus: A Fuse and a Solution

Longitudinal microbiome changes in children exposed to proton pump inhibitors

Celiac disease serology and gut microbiome following proton pump inhibitor treatment

An Autoimmunogenic and Proinflammatory Profile Defined by the Gut Microbiota of Patients With Untreated Systemic Lupus Erythematosus

Anti-Acid Drug Treatment Induces Changes in the Gut Microbiome Composition of Hemodialysis Patients

Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota

Compositional and functional aberrance of the gut microbiota in treatment-naïve patients with primary Sjögren's syndrome

Duodenal Dysbiosis and Relation to the Efficacy of Proton Pump Inhibitors in Functional Dyspepsia

Meta-analysis of the effects of proton pump inhibitors on the human gut microbiota

Gut microbiota regulation of T lymphocyte subsets during systemic lupus erythematosus

Altered gut fungi in systemic lupus erythematosus – A pilot study

Dysbiosis of oral microbiota is associated with systemic lupus erythematosus

The Microbiota in Systemic Lupus Erythematosus: An Update on the Potential Function of Probiotics

The Association of Long-Term Use of Proton Pump Inhibitors and Histamine H2 Receptor Antagonists with Clinical Complications in Patients with Severe Sepsis

Influence of gastric acid suppression on the structure and diversity of the jejunal microbiota in a rat model